Boai NKY Pharmaceuticals Ltd Asset Resilience Ratio
Boai NKY Pharmaceuticals Ltd asset resilience ratio. Boai NKY Pharmaceuticals Ltd (300109) has an Asset Resilience Ratio of 0.27% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Boai NKY Pharmaceuticals Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Boai NKY Pharmaceuticals Ltd (2010–2025)
Asset resilience ratio of Boai NKY Pharmaceuticals Ltd from 2010 to 2025. This chart shows how Boai NKY Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read debt load of Boai NKY Pharmaceuticals Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Boai NKY Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Boai NKY Pharmaceuticals Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥11.71 Million | 0.27% |
| Total Liquid Assets | CN¥11.71 Million | 0.27% |
Asset Resilience Insights
- Limited Liquidity: Boai NKY Pharmaceuticals Ltd maintains only 0.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Boai NKY Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Boai NKY Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Akzo Nobel NV
AS:AKZA |
Specialty Chemicals | 2.16% |
|
MITSU.CH.GRP ADR/5
F:M3C0 |
Specialty Chemicals | 1.61% |
|
LB Group Co Ltd
SHE:002601 |
Specialty Chemicals | 4.81% |
|
Hubei Feilihua Quartz Glass Co Ltd
SHE:300395 |
Specialty Chemicals | 6.18% |
|
Beijing Oriental Yuhong Waterproof Technology Co Ltd
SHE:002271 |
Specialty Chemicals | 1.24% |
|
Luxi Chemical Group Co Ltd
SHE:000830 |
Specialty Chemicals | 0.43% |
|
5N Plus Inc.
TO:VNP |
Specialty Chemicals | 12.56% |
|
Zhejiang Runtu Co Ltd
SHE:002440 |
Specialty Chemicals | 3.05% |
Boai NKY Pharmaceuticals Ltd Asset Resilience Ratio by Year (2010–2025)
Boai NKY Pharmaceuticals Ltd asset resilience ratio by year from 2010 to 2025. The table below shows the annual Asset Resilience Ratio data for Boai NKY Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.54% | CN¥23.79 Million ≈ $3.48 Million |
CN¥4.37 Billion ≈ $639.22 Million |
-0.16pp |
| 2024-12-31 | 0.71% | CN¥30.98 Million ≈ $4.53 Million |
CN¥4.37 Billion ≈ $639.77 Million |
-0.14pp |
| 2023-12-31 | 0.85% | CN¥34.20 Million ≈ $5.00 Million |
CN¥4.02 Billion ≈ $588.21 Million |
-0.01pp |
| 2022-12-31 | 0.86% | CN¥31.99 Million ≈ $4.68 Million |
CN¥3.71 Billion ≈ $543.41 Million |
-4.19pp |
| 2021-12-31 | 5.06% | CN¥201.71 Million ≈ $29.52 Million |
CN¥3.99 Billion ≈ $583.85 Million |
+3.97pp |
| 2020-12-31 | 1.09% | CN¥45.03 Million ≈ $6.59 Million |
CN¥4.15 Billion ≈ $606.61 Million |
+2.72pp |
| 2019-12-31 | -1.63% | CN¥-68.37 Million ≈ $-10.00 Million |
CN¥4.20 Billion ≈ $614.11 Million |
-1.22pp |
| 2018-12-31 | -0.41% | CN¥-9.48 Million ≈ $-1.39 Million |
CN¥2.30 Billion ≈ $337.02 Million |
-0.32pp |
| 2017-12-31 | -0.09% | CN¥-1.83 Million ≈ $-268.20K |
CN¥1.96 Billion ≈ $286.61 Million |
-3.22pp |
| 2016-12-31 | 3.13% | CN¥41.00 Million ≈ $6.00 Million |
CN¥1.31 Billion ≈ $191.68 Million |
+3.19pp |
| 2015-12-31 | -0.06% | CN¥-725.33K ≈ $-106.14K |
CN¥1.24 Billion ≈ $180.86 Million |
-- |
| 2010-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥357.81 Million ≈ $52.36 Million |
-- |
About Boai NKY Pharmaceuticals Ltd
Boai NKY Medical Holdings Ltd. engages in the fine chemical and precision medicine businesses in China and internationally. The company produces and sells polyvinyl pyrrolidone (PVP) series products, vinyl methyl ether/maleic anhydride copolymer (PVM/MA, Euroster) copolymer, and oral care products; and medical technology services, such as early tumor screening, molecular diagnostics, and precisio… Read more